Inhibition of 2,3-oxidosqualene cyclase (OSC; EC 5.4.99.7) is an interesting target for the design of new hypocholesterolemic drugs useful for the prevention of cardiovascular diseases.
Inhibition of 2,3-oxidosqualene cyclase (OSC; EC 5.4.99.7) is an interesting target for the design of new hypocholesterolemic drugs useful for the prevention of cardiovascular diseases. 1) OSC catalyzes the conversion of (S)-2,3-oxidosqualene to lanosterol which is probably one of the most complex enzymatic reaction described so far. A huge number of studies have been devoted to the elucidation of its mechanism of action for more than four decades.
2) Although either kinetic or structural approaches have been recently described, 3 ) none of them is really able to give a full picture of the cyclisation/rearrangement process. In this perspective, crystallographic study of this enzyme could be very helpful but has still to be performed. However, the crystal structure of a closely-related enzyme: squalene-hopene cyclase, has been recently determined.
4) Moreover, the photolabeling of this enzyme 5a,b) with [ 3 H]Ro48-8071, a molecule known as a potent inhibitor of both lanosterol synthase and squalenehopene cyclase, has also shed some light on this issue. Finally an important review 5c) on the mechanistic aspects of the synthesis of polycyclic triterpene gives a general picture on the role of the enzyme in protecting the intermediate carbocations against addition of water allowing the polycyclisation to proceed. We recently described inhibitors of OSC 6 ) based on the 6-isoquinolinol structure. This template which is supposed to mimic a postulated pro-C8 carbocation intermediate I (Fig. 1 ) along the cyclisation-rearrangement pathway to lanosterol, was initially developed by Rahier and coworkers. 7) Our study focused on the investigation of the structural requirements of 6-isoquinolinol-based inhibitors for OSC inhibition. Unfortunately, the obtained inhibitors remained synthetically poorly accessible due to the presence of several chiral centers. Nevertheless, we have determined some important features that can be used for the design of more readily accessible molecules. In this publication, we present our efforts based on previous results, to obtain new potent and easily accessible inhibitors of OSC.
Chemistry
The synthetic route to the key intermediates leading to the compounds listed in Tables 1 and 2 is shown in Chart 1. Reductive amination of the carbonyl compounds 1a-c 6) with NH 4 OAc and NaBH 3 CN 8) in CH 3 OH provided amino derivatives which were acylated using TFAA in THF. Chromatographic separation of the isomers afforded b and a isomers 2a-c and 3a, b in a 85/15 ratio. Assignments of the stereochemistry of 2a-c and 3a, b were made by 1 H-NMR analysis using the chemical shift of the proton borne by C-6. 9) Deprotection of the trifluoroacetyl group was carried out with K 2 CO 3 in refluxing aqueous CH 3 OH (Method A).
Deprotection of the N-Boc group of 2c (Chart 2) was achieved in a conventional way with 3 N HCl in CH 3 OH to afford 6 which was alkylated with n-bromododecane in CH 3 CN (Method B). Compound 7 was deprotected using method A to obtain 8a. Preparation of 8d was achieved using CH 3 I as alkylating agent with NaH in N,N-dimethylformamide (DMF) followed by hydrolysis of the trifluoroacetyl moiety. The synthetic route to 8b, c, e-h is shown in Chart 3. The intermediates 4a and 5b were converted to 9a and 10b by reductive alkylation with HCHO and NaBH 3 CN (Method C). 10) Removal of the protective groups of 9a and 10b was achieved by either hydrogenolysis for 9a or the Olah's method 11) for 10b to afford 11 and 12, respectively. Alkylation of 12 with n-bromododecane in CH 3 CN (Method B) afforded 8b. The isoquinolines 8c, e-h were obtained by either alkylation using 1-bromo-6,6-dimethyl-2-hepten-4-yne or a reductive alkylation when aldehydes or ketones were commercially available (Method D), or by a two-step procedure involving the formation of an amide followed by reduction with Red-Al (Method E). The preparation of piperidineethanamine derivatives (Tables 3, 5) is illustrated in Charts 4-6. Aldol condensation between 4-piperidone 13 and ethyl isobutyrate in the presence of lithium diisopropylamide (LDA) led to 4-hydroxy-piperidine 12) 14 which was subsequently dehydrated with SOCl 2 in CHCl 3 to give 15 (Chart 4). Hydrogenation of the double bond and hydrogenolysis of the benzyl group of 15 proceeded in one step with 5% Pd/C as catalyst under 80 atm H 2 pressure to afford 16. Alkylation of 16 gave 17 which was hydrolyzed with NaOH to afford 18. Reaction of acid 18 with SOCl 2 followed by condensation of the resulting acid chloride with various amines, afforded amide derivatives 19a-f, j, k (Method F) which were reduced with Red-Al (Method G). An alternative original three-step synthesis has been developed for the preparation of 20i, l, m, p, s, u-ab (Chart 5) which involved a Mannich reaction (Method H) 13a,b) between commercially available 4-isopropylpyridine, formaldehyde and secondary amines in the first step. Hydrogenation of the pyridine ring with PtO 2 as catalyst in the second step was followed by alkylation of the resulting piperidine derivatives using methods B, D or E. The preparation of compounds 20n, o, q, r, t was performed following the pathways described in Chart 6. Hydrazinolysis of 20ac and subsequent acylation of the resulting amine with 5-methyl hexanoyl chloride in CH 2 Cl 2 in the presence of Et 3 N gave 20o. Compound 20n was prepared by hydrogenation of the unsaturated bonds of 20p with Pd/C as catalyst. Quaternary ammonium salt 20t was obtained by reacting 20s with CH 3 I in ether. Refluxing 20ad with 4-methyl pentaneamine in toluene gave 20q which was reduced following Method G. Preparation of bipiperidine derivatives (Table 4) is shown in Chart 7. Michael addition of acrylonitrile with 24 afforded
25.
14) Hydrogenation of 25 and simultaneous cyclization of the resulting amino ester was performed in a Parr apparatus with Raney nickel as catalyst and afforded 26 in good yield. Catalytic hydrogenation of the pyridine ring of 26 with PtO 2 in AcOH followed by alkylation of the resulting compound 27 yielded 28. Reduction of the piperidone 28 with LiAlH 4 led to 21a. This compound was finally methylated following Eschweiler-Clarke 15a-c) procedure to provide 21b.
Results and Discussion
OSC inhibition was measured using rat liver microsomes and synthetic (R,S)-2,3-oxidosqualene. The inhibition potencies were expressed as IC 50 values. The 6-isoquinolinol derivative LF 05-0038 (see Table 1) 6) was designed as a mimic of the postulated pro-C8 carbocation intermediate I along the cyclisation-rearrangement pathway, i.e. the second intermediate step of the 2,3-oxidosqualene cyclization (Fig. 1) . The hydroxyl group of 6-isoquinolinol was the equivalent of the hydroxyl group of the A ring system in the intermediate I.
On the other hand, the positive charge borne by the protonated nitrogen was supposed to mimic the C-8 carbocation of I. Most of the results obtained with various analogues were consistent with this hypothesis. 6) In this study we turned our attention to several features of the 6-isoquinolinol derivatives with the aim of finding synthetically more accessible inhibitors with more drug-like structures. We first investigated the importance of the hydroxyl group. Indeed, the cyclization process mediated by the enzyme is triggered by the protonation of the epoxide and the proton donor is very likely the Asp456. 5c, 20) We thus introduced several types of amine in place of the hydroxyl group in order to increase the affinity for the active site by the putative resulting ionic interaction with the Asp456. A similar approach was fruitful in the case of squalene based inhibitors. 1b) Table 1 shows that the primary amine 8a is much less active than the parent hydroxylated analogue. However, the corresponding dimethylated tertiary amine 8c 18) is about two orders of magnitude more potent than the primary amine 8a and about two-fold more potent than the corresponding hydroxylated compound. As previously observed for the corresponding a-hydroxylated analogue, 6 ) the a-isomer 8b is about ten-fold less active than the b-isomer 8c. The monomethyl derivative 8d is fifty-fold less active than the dimethyl derivative 8c. These results are consistent with the formation of an ionic interaction with the Asp456 although the part played by the methyl groups is still unclear. Table 2 presents a few derivatives in which the saturated dodecyl chain was replaced by various unsaturated substituents intended to better mimic the terpenic chain of the natural substrate. The chains supposed to mimic the squalenoid moiety encountered in terbinafine 25) and naftifine, 26) led to more potent compounds 8f and 8g. In order to simplify the core of these inhibitors, we opened the ring, mimicking the A ring system of the pro-C8 carbocation intermediate I, 17) and removed the angular methyl group leading to the achiral 4-piperidineethanamine derivatives. 19) We have indeed shown in a previous study, 6) that the angular methyl group was not necessary for the activity. The flexibility brought by the ring opening seems to be favorable to the activity as shown by the resulting primary amine 20a found to be about ten-fold more potent than the corresponding bicyclic analogue 8a. We then investigated in details the influence of the substituents borne by the terminal nitrogen atom. Among the secondary amines, the smaller the substituent was, the better the activity: the IC 50 was 0.34 mM for 20b, 0.66 mM for 20c and Ͼ50 mM for 20d-f. The same trend was observed with tertiary amines, where the best activity, similarly to the bicyclic series, was observed for the dimethyl derivative 20i (IC 50 ϭ0.12 mM). Finally, we synthesized the amides 20g and 20h.
The decrease of activity observed between 20h and 20c seems to be consistent with the existence of an ionic interaction. The last structural change made on this part of the molecule was the insertion of the nitrogen atom in a ring, resulting into two 3-(piperidinyl)-piperidine derivatives 21a and 21b (Table 4 ). This new constraint proved to be detrimental to the activity: 21a, which can be viewed as a rigid analogue of the active compound 20c, was found inactive (i.e. IC 50 Ͼ 50 mM) whereas the corresponding methylated analogue 21b proved to be a weak inhibitor. A similar structure activity relationship has been published for azasqualene based inhibitors of pea seedlings and rat liver OSC. 24) Having optimized the core structure i.e. a b,b-dimethyl-4-piperidineethanamine, we then studied different replacements of the saturated dodecyl chain (Table 5 ). In our previous work, we found that the optimal carbon chain length corresponded to a 10 to 12 carbon unit substituent. In the present study we confirmed that a very short chain (a methyl group) led to an inactive compound 20m. The branched chain of terbinafine led to an active compound 20p. Its complete reduction afforded 20n showing the same activity. In contrast, introduction of polar functions such as amides or amines in the chain afforded weak inhibitors: 20o and 20r, except 20q which is rather active. As previously observed 6, 16) in related series, the conversion of the tertiary amine of 20i into a tertiary amide afforded an almost equipotent derivative 20s. In contrast, the quaternarisation of the amine of this derivative 320 Vol. 50, No. 3 led to 20t which was six-fold less active. Different compounds bearing aromatic containing substituents were then synthesized as amides and their corresponding amines. In general, the amines proved to be more active than the amides. For example, 20ab is six-fold more active than 20aa. This trend culminates with compounds 20w and 20x, this one being the most potent inhibitor of this series with an IC 50 of 0.018 mM.
The publication of the crystal structure of squalene-hopene cyclase led us to construct a 3D model of the rat OSC starting from the sequence alignment suggested by Wendt et al.
4)
The conformation of the inserted loops was then deduced from similar sequences encountered in proteins structures of the Protein Data Bank according to a well-validated homology modeling methodology.
21) The amino-acids close to the site which triggers the cyclisation, i.e. around the Asp456 (or the corresponding Asp376 of the squalene-hopene cyclase), are well conserved among the two enzymes, except Asp377 which is only present in squalene-hopene cyclase.
4,5c) This suggests a high similarity of the active sites of the two enzymes at least in this region. Consequently, although our model should be confirmed by further studies, it could be tentatively used a posteriori to explain some of the features of the structure activity relationships observed in our series of inhibitors. The crystal structure of the squalene-hopene cyclase co-crystallized with a competitive inhibitor: N,NЈ-dimethyldodecylamine-N-oxide shows that the nitrogen atom of this inhibitor is close to the Asp376. It was previously shown 6, 16) that the 6-isoquinolinol-based inhibitors of OSC behave as competitive inhibitors. In the hypothesis that the closely-related amino analogues behave similarly, their binding to the active site should position the exocyclic protonated nitrogen nearby the Asp456 which corresponds to Asp376 in hopene-squalene cyclase. The docking of the two inhibitors 8c and 20x was made starting from this assumption (Figs. 2,  3 ). The cavity surrounding the Asp456 can easily accommodate one or two methyl groups but not bulkier groups without destroying the possible salt bridge. In the case of compound 8c, the two methyl groups come in close contact to the aromatic ring of Trp388 (Figs. 2, 3 ). However a dramatic decrease of potency was observed in the piperidine series and with compounds bearing moieties bulkier than the dimethylamino group such as 20d, 20e, 20f, 20j, 20k, 20l, 21a and 21b. However, this model does not explain the very bad activities of the primary amine 8a and the secondary amine 8d. It should not be forgotten that this enzyme is membrane bound and that the inhibitor, similarly to the substrate, 4) should diffuse to the active site through the phospholipid bilayer. The amount of the inhibitor available at the active site is thus depending on the partitioning of the inhibitor between the aqueous phase and the membrane, and a direct analysis of the structure activity relationships is consequently difficult. Fig. 4 shows a possible mode of binding of the best inhibitor 20x in the active site of the enzyme. It is worthnoting that the flexibility brought by the opening of the bicycle induces a better positioning of the dimethylamino group of this derivative towards the Asp456 and Trp388, optimizing ionic interaction and Van der Waals contacts (the distance between the nitrogen of 20x and the closest oxygen of Asp486 is 2.84 Å versus 3.23 Å for 8c). A H-bond between the hydrogen of the cyclic ammonium and the oxygen of Tyr99 is made possible with this compound (the distance between the corresponding atoms in the case of 8c is 3.99 Å compared to 2.54 Å with 20x). Finally, the 4-chlorophenoxy moiety is lo- The solvent accessible surface of the residues is visualized except for Trp582, Phe697 and Phe522 (in yellow) to make the inhibitor (in magenta) more perceptible. This picture shows the interactions between the two methyl groups and the exocyclic ammonium moiety of the inhibitor respectively with Trp388 and Asp456. cated in a cavity suitably adapted and highly hydrophobic where the Phe697 develops a clear T-shape interaction with the phenyl of 20x and where the chlorine atom is surrounded with aliphatic and aromatic residues (Fig. 5 ). All these features may explain the high potency of this inhibitor. A closer look at these docking models could help the design of more potent inhibitors, for instance, replacing the chlorine atom of 20x by a hydrophobic group such a phenyl which could bring a supplementary interaction surface. It can be noticed that halogenated aryl substituents have been successfully introduced in Roche and Karl Thomae OSC inhibitors. 1c,d) In conclusion, based on a good OSC inhibitor (LF 05-0038) obtained in a previous study, we designed structurally simpler molecules and found a rather potent inhibitor: 20x. Contrary to LF 05-0038, this molecule, which is achiral and readily accessible, deserves further biological tests, in particular in vivo studies. Furthermore, the recent availability of the crystal structure of hopene-squalene cyclase led us to construct a 3D model of OSC that could help designing new inhibitors of this enzyme.
Experimental
Melting points were determined on a Büchi melting point apparatus and were uncorrected. IR spectra were measured on a Perkin-Elmer 782 spectrophotometer.
1 H-and 13 C-NMR spectra were obtained on a Bruker AC300 spectrometer using tetramethylsilane as internal standard. MS spectra were measured with a Nermag Model R30-10 spectrometer. Structural assignments for all new compounds are consistent with their spectra. Elemental analyses were performed on a Perkin-Elmer 240C apparatus. 
(1H)-isoquinolinecarboxylic Acid Phenylmethyl Ester (3a)
To a solution of 1a (65 g, 20 mmol) in 700 ml of methanol was added ammonium acetate (153 g, 2 mol), the pH of the resulting solution was adjusted at 7.3 with AcOH then NaBH 3 CN (20 g, 30 mmol) was added portionwise. The mixture was stirred for 2 d at room temperature then concentrated. The residue was extracted with EtOAc, washed with water, dried (MgSO 4 ) and evaporated to afford 3,5,6,7,8,8a-hexahydro-5,5,8a-trimethyl-6-amino-2(1H)-isoquinolinecarboxylic acid phenylmethyl ester (52 g, 82%) as an oil. To a solution of this product (50 g, 0.15 mol) and Et 3 N (25.5 ml) in 200 ml of THF was added dropwise TFAA (25.8 ml, 0.18 mol) in 50 ml of THF keeping the temperature at 0°C then the mixture was stirred overnight at room temperature. After evaporation, the residue was dissolved in ether, washed with 1 N HCl, with water, dried (MgSO 4 ) and evaporated. Purification of the oily residue by silica-gel column chromatography (isopropyl ether-methylcyclohexane, 9/1) gave 2a (37.1 g, 59%) as a solid: mp 138°C and 3a (6.5 (6b b,8ab b)-6-Amino-3,5,6,7,8,8a-hexahydro-5,5,8a-trimethyl-2(1H )-isoquinolinecarboxylic Acid Phenylmethyl Ester (4a) Method A A mixture of 2a (35 g, 80 mmol), of K 2 CO 3 (115 g, 0.8 mol) in 500 ml of CH 3 OH and 100 ml of H 2 O was refluxed for 8 h. Upon cooling at room temperature, the mixture was evaporated and the residue was partitioned between EtOAc and water. The organic solution was washed with water, dried (MgSO 4 ) and concentrated to give 27 g (100%) of 4a. (6b b,8ab b)-N-Trifluoroacetyl-1,2,3,5,6,7,8,8a-octahydro-5,5,8a-trimethyl-6-isoquinolineamine (6) A solution of 2c (3.27 g, 8.37 mmol) in methanol (30 ml) and 3 N HCl (4.2 ml) was refluxed for 6 h. After cooling, the solution was evaporated, the resulting residue was poured into ice-cold 1 N NaOH (15 ml) and extracted with EtOAc. The combined organic layer was washed with brine, dried over MgSO 4 and evaporated to afford 6 as a white solid (2.1 g, 87.5%): mp 160°C. 4 mmol) and of 1-bromododecane (2.25 g, 9.03 mmol) in 50 ml of acetonitrile was refluxed for 8 h. After cooling, the mixture was poured into brine and extracted with EtOAc. The combined organic layer was washed with water, dried (MgSO 4 ) and concentrated in vacuo. The oily residue was separated on a silica gel column eluting with a solvent mixture of hexane-EtOAc (9/1) to afford 7 as a solid (3.2 g, 85%): mp 80°C. 1 (6b b ,8ab b )-N-Methyl-1,2,3,5,6,7,8,8a-octahydro-2-dodecyl-5,5,8a-trimethyl-6-isoquinolineamine (8d) A solution of 7 (3.5 g , 11 mmol) in 20 ml of DMF was carefully added to a suspension of NaH (0.43 g, 60% dispersion in mineral oil). After completion of the addition, the mixture was heated at 40°C for 1 h. The mixture was cooled, iodomethane (0.8 ml, 13 mmol) was then added and the reaction mixture was stirred at room temperature for 48 h. The mixture was poured into water and extracted with ether. The organic phase was washed with water, dried (MgSO 4 ) and evaporated to give (6b,8ab)-N-methyl-N-trifluoroacetyl-1,2,3,5,6,7,8,8a-octahydro-2-dodecyl-5,5,8a-trimethyl-6-isoquinolineamine as a solid (2.6 g, 72%): mp 60°C. 2.5 g (5 mmol) of the previous compound was refluxed for 48 h in 200 ml of methanol, 50 ml of water and K 2 CO 3 (14.6 g, 0.1 mol). After cooling, the reaction mixture was evaporated. The residue was partitioned between water and methylene chloride. The organic phase was washed with water, dried (MgSO 4 ) and concentrated in vacuo. The residue was purified by chromatography with CH 2 Cl 2 -CH 3 OH-NH 4 OH (98.5/1/0.5) as eluent to give 8d as an oil (1.5 g, 79%). (6b b,8ab b)-3,5,6,7,8,8a-Hexahydro-6-dimethylamino-5,5,8a-trimethyl-2(1H)-isoquinolinecarboxylic Acid Phenylmethyl Ester (9a). Method C To a solution of 4a (27 g, 80 mmol) in 500 ml of acetonitrile were added 74 ml of formaldehyde (37% solution in water). The pH of the resulting mixture was adjusted to 7.5 by addition of acetic acid. NaBH 3 CN (15.5 g, 0.25 mol) was added portionwise, then the reaction mixture was stirred at room temperature for 12 h and evaporated. The residue was taken up with 1 N NaOH and extracted with EtOAc. The organic layers were washed with water, dried (MgSO 4 ) and concentrated. (6a a,8ab b)-3,5,6,7,8,8a-Hexahydro-6-dimethylamino-5,5,8a-trimethyl-2(1H)-isoquinolinecarboxylic Acid Ethyl Ester (10b) The titled compound was prepared using the same procedure as described above, starting from 5b (1.2 g, 4.5 mmol) in 60% yield as an oil (0.82 g). (6b b,8ab b)-N,N-Dimethyl-1,2,3,5,6,7,8,8a-octahydro-5,5,8a-trimethyl-6-isoquinolineamine (11) A mixture of 9a (21.5 g, 60 mmol) and 3.5 g of 5% Pd/C in 250 ml of acetic acid was stirred at room temperature under 1 atm of H 2 . The catalyst was filtered and the solvent was removed. The residue was taken up with 1 N NaOH and extracted with ether. The organic solution was washed with water, dried over MgSO 4 and concentrated to give 11 (12.6 (6a a,8ab b)-N,N-Dimethyl-1,2,3,5,6,7,8,8a-octahydro-5,5,8a-trimethyl-6-isoquinolineamine (12) Trimethylsilyl chloride (4 ml) were carefully added at room temperature to a solution of 10b (0.8 g, 2.7 mmol) and NaI (5.2 g, 34 mmol) in 15 ml of acetonitrile. The resulting mixture was refluxed for 24 h. After cooling the solvent was removed under reduced pressure and the residue was taken up with 1 N HCl, then washed with ether. The aqueous phase was made basic with 1 N NaOH and extracted with ether. The ethereal phase was washed with water, dried over MgSO 4 and the solvent was removed under reduced pressure to provide 12 as a crude solid (0.5 g, 77%): mp 103°C. 1 (6a a,8ab b)-N,N-Dimethyl-1,2,3,5,6,7,8,8a-octahydro-2-dodecyl-5,5,8a-trimethyl-6-isoquinolineamine (8b) The title compound was prepared following Method B starting from 12 (0.42 g, 1.89 mmol), n-bromododecane (0.5 g, 2 mmol) and K 2 CO 3 in CH 3 CN to afford 8b (37%) as an oil which was converted into its oxalate: mp 139°C. 3 g, 12 .5 mmol) in 60 ml of methanol was adjusted to 7 by addition of AcOH, NaBH 3 CN (0.82 g, 13.0 mmol) was then carefully added. The resulting solution was stirred overnight. After evaporation, the residue was poured into ice-cooled dilute NaOH and extracted with EtOAc. The organic layer was washed with brine, dried (MgSO 4 ) evaporated and purified by silica gel column chromatography (toluene, iso-PrOH 98/2) to give 8c (3.25 6-isoquinolineamine (8g) . Method E 1,1Ј-Carbonyldiimidazole (2.6 g, 16 mmol) was added portionwise to a solution of trans-cinnamic acid (2.4 g, 16 mmol) in 50 ml of THF and the reaction mixture was stirred at room temperature for 0.5 h then heated at 50°C for 1 h. After cooling at 5°C, a solution of 11 (3 g, 13.5 mmol) in 40 ml of THF was added dropwise. The reaction mixture was stirred overnight, diluted with water then extracted with ether. The organic phase was washed with water, dried (MgSO 4 ) and concentrated to leave an oil which was purified by chromatography on silica gel eluting with a mixture of CH 2 Cl 2 -CH 3 OH-NH 4 OH (9/0.9/0.1) to afford (6b,8ab)-N,N-dimethyl-1,2,3,5,6,7, 8,8a-octahydro-2-(3-phenyl-2-propenoyl)-5,5,8a-trimethyl-6-isoquinolineamine (2.76 g, 59%). This material (1.5 g, 4.26 mmol) was dissolved in 30 ml of toluene and a 70% solution of Red-Al in toluene (2.5 ml, 8.6 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 2.5 h then cooled to 0°C. A solution (50 ml) of 5 N NaOH was carefully added and the resulting mixture was allowed to warm to room temperature with stirring for 0.5 h. Ether was then added and the mixture was washed with water, dried then concentrated to dryness to give 8g (1.4 g, 100%) as a pale-yellow oil. This oil was converted to a tosylate: mp 210°C. 1 (6b b,8ab b)-N,N-Dimethyl-1,2,3,5,6,7,8,8a-octahydro-2-(3,3-diphenyl-2-propen-1-yl)-5,5,8a-trimethyl-6-isoquinolineamine (8h) The title compound was prepared following Method E starting from 11 (3 g, 13.5 mmol), 3-phenyl-2-propenoic acid (3.6 g, 16 mmol) and carbonyl diimidazole (2.6 g, 16 mmol) in THF (50 ml) to afford the corresponding amide. This was reduced with RedAl (7 ml, 24 mmol) to give 8h (5.1 g, 95%) which was converted into its oxalate: mp 150°C. 1 Hydroxy-a a ,a a -dimethyl-1-phenylmethyl-4 -piperidineacetic Acid Ethyl Ester (14) A solution of diisopropylamine (152.8 ml, 1.09 mol) in dry THF (100 ml) was stirred at Ϫ50°C under an atmosphere of N 2 and a 2.5 M solution of nBuLi in hexane (400 ml, 1 mol) was added dropwise. The mixture was stirred at Ϫ50°C for 45 min, then 2-methylpropanoic acid ethyl ester (121.8 ml, 0.91 mol) in THF (100 ml) was added dropwise and stirring was maintained during 1 h. A solution of 1-phenylmethyl-4-piperidone 13 (120.5 ml, 0.68 mol) in THF (100 ml) was added dropwise at Ϫ50°C, then the reaction mixture was warmed to room temperature overnight. Saturated aqueous NH 4 Cl (400 ml) was added, and the resulting mixture was then extracted with ether. The organic layer was washed with brine, dried over MgSO 4 and concentrated in vacuo to leave an oil which was distilled under reduced pressure to afforded 14 (172. Hydrochloride salt was prepared in iso-PrOH solution by adding HCl gas to afford 15 as a white powder, which was recrystallized from iso-PrOH (38.9 g, 74%): mp 208°C. a a,a a-Dimethyl-4-piperidineacetic Acid Ethyl Ester (16) A solution of 15 (54.6 g, 0.169 mol) in CH 3 OH (800 ml) was hydrogenated over 5% Pd/C (3 g) at 70°C under 80 atm H 2 pressure. After completion of the reaction, the mixture was filtered, and the filtrate evaporated in vacuo. The solid residue was quenched with 10 N NaOH, then extracted with CH 2 Cl 2 . The extracts were washed with brine, dried over MgSO 4 and evaporated in vacuo to give 16 as a yellow oil (28.6 g, 85%). IR (neat) 3150, 1730 cm a a,a a-Dimethyl-1-dodecyl-4-piperidineacetamide (19a). Method F The compound 18 (17.9 g, 0.048 mol) was added portionwise to SOCl 2 (100 ml, 1.37 mol), the mixture was then refluxed for 7.5 h. The solution was evaporated in vacuo to afford a,a-dimethyl-1-dodecyl-4-piperidineacetyl chloride hydrochloride which was used in the following reactions without purification.
(1H
Liquid ammonia (80 ml) at Ϫ5°C was carefully added to a solution of the product obtained in the previous step (8.6 g, 0.022 mol) in a 2/1 mixture of toluene-CH 2 Cl 2 (100 ml). After stirring for 72 h at room temperature, the reaction mixture was poured in water then extracted with EtOAc. The organic extracts were washed with water, dried over MgSO 4 The following compounds were prepared according to Method F. 1-Dodecyl-N,a a,a a-trimethyl-4-piperidineacetamide (19b) The title compound was prepared from a,a-dimethyl-1-dodecyl-4-piperidineacetyl chloride hydrochloride (25 g, 63 mmol) and methaneamine (300 ml) in of 19a (2.95 g, 8 .7 mmol) in 80 ml of toluene. The resulting mixture was stirred for 1 h at room temperature, then heated to reflux for 3 h. After cooling, 3 N NaOH (50 ml) was added dropwise and the mixture stirred for 24 h. The organic phase was washed with dilute NaOH, then with brine, dried (MgSO 4 ) and concentrated to dryness to afford a crude product which was purified by chromatography with EtOAc-CH 3 OH-NH 4 OH (98.5/1/0.5) as eluent to give 20a as an oil (1.8 g, 64%). This compound was converted into its fumarate salt: mp 100-120°C. 1 4 mmol) and Et 3 N (8.6 ml, 62 mmol) in CH 2 Cl 2 (50 ml). The resulting mixture was stirred at room temperature for 20 h. The reaction mixture was poured into ice-cooled 1 N NaOH, then extracted with CH 2 Cl 2 . The organic phase was washed with water, dried (MgSO 4 ) and evaporated to afford the title compound (3.9 g, 86%) as a solid: mp 65°C. . Method H To a solution of 4-isopropylpyridine (100 g, 0.82 mol), formaldehyde (37% solution in water, 200 ml) in acetic acid (800 ml), dimethylamine (40% solution in water, 300 ml) was added dropwise then the resulting solution was refluxed for 3 d. Upon cooling, formaldehyde (100 ml) and dimethylamine (150 ml) were again added and the reaction mixture was refluxed for 2 extra days. The solvent was concentrated and 35% NaOH solution (400 ml) was carefully added upon cooling. The aqueous solution was washed with brine, dried over MgSO 4 and evaporated in vacuo to give an oil. This oil was purified by vacuum distillation (bp 64-66°C/0.3 mmHg) to give 22i (61.7 g, 42% b b,b b-Dimethyl-N,N-dimethyl-4-piperidineethanamine (23i) In a Parr apparatus, 22i (123 g, 0.69 mol) was dissolved in acetic acid (900 ml) and PtO 2 (12 g) was added. The reaction mixture then was stirred under a 1000 psi hydrogen pressure at 80°C for 7 h and thereafter the catalyst was filtered. The filtrate was evaporated in vacuo to give an oily residue which was dissolved in water, basified under efficient cooling with 35% NaOH and extracted with CHCl 3 . The organic extracts were washed with brine, dried (MgSO 4 ) and concentrated to afford 23i as an oil (127 g, 100%) pure enough to be used in the next step.
1-[2-Methyl-2-(4-piperidinyl)propyl]piperidine (23l) The compound was prepared from 22l (10 g, 45.8 mmol) as described above in a quantitative yield and was used in next step without further purification. 6 mmol) and hydrazine hydrate (4 ml, 82.5 mmol) in ethanol (100 ml) was heated under reflux for 0.5 h. The reaction mixture was poured into ice-cooled 5 N sodium hydroxide, then extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 and evaporated to leave 4-[2-(dimethylamino)-1,1-dimethylethyl]-1-piperidine-propanamine as an oil (7.9 g, 86%). To an icecooled solution of 4-[2-(dimethylamino)-1,1-dimethylethyl]-1-piperidinepropanamine (4.2 g, 17.4 mmol) and Et 3 N (12 ml, 86 mmol) in CH 2 Cl 2 (50 ml) was added dropwise a solution of 5-methyl hexanoyl chloride (2.6 g, 17.5 mmol) in CH 2 Cl 2 (25 ml) and the resulting mixture was stirred at room
